Status:
COMPLETED
ILAs in CT Lung Cancer Screening Population
Lead Sponsor:
Lahey Clinic
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Interstitial Lung Disease
IPF
Eligibility:
All Genders
18-80 years
Brief Summary
Interstitial Lung Abnormalities (ILA) have been previously defined as nondependent changes affecting more than 5% of any lung zone on computed tomography (CT) scans of the lung. Several studies sugges...
Detailed Description
Investigators propose a retrospective, single-center study with following aims: 1. Characterize the prevalence and incidence of ILA at baseline and 5 year follow-up, respectively, and associated imag...
Eligibility Criteria
Inclusion
- Patient who have undergone low-dose screening CT scan for lung cancer as part of the LHMC CTLS program from January 1, 2012 through September 30, 2014, with an in-network PCP.
Exclusion
- Any patient that does not meet inclusion criteria.
Key Trial Info
Start Date :
January 30 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
1703 Patients enrolled
Trial Details
Trial ID
NCT04503044
Start Date
January 30 2021
End Date
June 30 2021
Last Update
August 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lahey Hospital and Medical Center
Burlington, Massachusetts, United States, 01805